We are live on ! Find out more
ELV icon

Elevance Health

1,030 hedge funds and large institutions have $64.3B invested in Elevance Health in 2019 Q2 according to their latest regulatory filings, with 98 funds opening new positions, 401 increasing their positions, 378 reducing their positions, and 129 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more repeat investments, than reductions

Existing positions increased: 401 | Existing positions reduced: 378

5% more call options, than puts

Call options by funds: $595M | Put options by funds: $568M

0.56% more ownership

Funds ownership: 88.33%88.9% (+0.56%)

1% less capital invested

Capital invested by funds: $65B → $64.3B (-$732M)

4% less funds holding

Funds holding: 1,0741,030 (-44)

20% less funds holding in top 10

Funds holding in top 10: 4536 (-9)

24% less first-time investments, than exits

New positions opened: 98 | Existing positions closed: 129

Holders
1,030
Holders Change
-44
Holders Change %
-4.1%
% of All Funds
22.37%
Holding in Top 10
36
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-20%
% of All Funds
0.78%
New
98
Increased
401
Reduced
378
Closed
129
Calls
$595M
Puts
$568M
Net Calls
+$27M
Net Calls Change
-$36.1M
Name Holding Trade Value Shares
Change
Change in
Stake
AAP
176
Ardsley Advisory Partners
Connecticut
$26.7M +$12.8M +47,000 +99%
KBC Group
177
KBC Group
Belgium
$26.5M -$169K -619 -0.7%
TIM
178
Triodos Investment Management
Netherlands
$26.2M +$1.25M +4,590 +5%
M&T Bank
179
M&T Bank
New York
$26M -$46.7K -171 -0.2%
Truist Financial
180
Truist Financial
North Carolina
$25.6M -$333K -1,220 -1%
RPAM
181
Rhenman & Partners Asset Management
Sweden
$25.4M +$4.47M +16,355 +22%
Macquarie Group
182
Macquarie Group
Australia
$24.8M -$3.4M -12,454 -12%
HCM
183
Hoplite Capital Management
New York
$24.5M -$11.8M -43,078 -33%
Calamos Advisors
184
Calamos Advisors
Illinois
$23.9M -$41.6M -152,429 -64%
AIG
185
American International Group
New York
$23.9M -$513K -1,877 -2%
AssetMark Inc
186
AssetMark Inc
California
$23.8M +$1.38M +5,056 +6%
FAF
187
Fjarde Ap-fonden
Sweden
$22.2M +$54.6K +200 +0.3%
First Trust Advisors
188
First Trust Advisors
Illinois
$21.9M -$50.7M -185,672 -71%
NONA
189
Ninety One North America
New York
$21.7M +$1.51M +5,541 +8%
CS
190
Candriam SCA
Luxembourg
$21.3M +$2.19K +8 +0%
FIM
191
Foresters Investment Management
New York
$21M -$11.2M -40,995 -35%
BNP Paribas Asset Management
192
BNP Paribas Asset Management
France
$21M -$31.4K -115 -0.2%
TCM
193
Tran Capital Management
California
$21M -$6.69M -24,476 -25%
ERSOT
194
Employees Retirement System of Texas
Texas
$20.9M -$476K -1,743 -2%
OPERF
195
Oregon Public Employees Retirement Fund
Oregon
$20.9M -$7.45M -27,268 -27%
WT
196
Whittier Trust
California
$20.7M +$406K +1,487 +2%
SDIC
197
South Dakota Investment Council
South Dakota
$20.7M +$10.8M +39,713 +118%
JIR
198
James Investment Research
Ohio
$20.6M +$2.3M +8,422 +13%
SGA
199
Sector Gamma AS
Norway
$20.6M +$9.31M +34,094 +87%
MIM
200
MetLife Investment Management
New Jersey
$20M -$593K -2,170 -3%

ELV Hedge Fund Activity: Q2 2019 in Review

1,030 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Elevance Health (ELV) for Q2 2019, worth a combined $64.3B — down 1.1% from $65B a quarter earlier.

Sellers outnumbered buyers: 129 funds closed out of ELV and 98 opened new positions — a net loss of 31 holders — while 378 trimmed existing stakes and 401 added.

The largest buyer was TCI Fund Management, opening a new position worth an estimated $823M. The largest seller was T. Rowe Price Associates, cutting an estimated $636M.

  • 1,030 institutional investors held Elevance Health (ELV) as of Q2 2019, down from 1,074 in Q1 2019.
  • Funds reported $64.3B of Elevance Health stock for Q2 2019, down 1.1% quarter-over-quarter.
  • 98 funds opened new Elevance Health positions in Q2 2019 and 129 closed out, a net change of -31 holders.
  • The largest Elevance Health buyer in Q2 2019 was TCI Fund Management, an estimated $823M added.
  • The largest Elevance Health seller in Q2 2019 was T. Rowe Price Associates, an estimated $636M sold.

Based on aggregated 13F filings for Q2 2019.